Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALIMNASDAQ:CLSNNASDAQ:EVOKNASDAQ:GNPXNASDAQ:ITRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALIMAlimera Sciences$5.54$5.55$2.61▼$5.65$290.24M1.25376,318 shsN/ACLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsEVOKEvoke Pharma$2.65-2.6%$3.06$1.94▼$12.32$4.06M-0.04124,798 shs3,959 shsGNPXGENPREX$0.26-1.2%$0.28$0.20▼$3.97$7.24M-0.54.16 million shs528,668 shsITRMIterum Therapeutics$0.92-4.2%$0.99$0.81▼$3.02$38.56M2.791.07 million shs564,205 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALIMAlimera Sciences0.00%0.00%0.00%0.00%-0.18%CLSNImunon0.00%0.00%0.00%0.00%0.00%EVOKEvoke Pharma-2.03%+1.92%-10.17%+28.02%-59.10%GNPXGENPREX-2.24%+12.81%-10.61%+1.02%-86.47%ITRMIterum Therapeutics-2.87%-7.17%-4.77%-16.78%-19.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALIMAlimera SciencesN/AN/AN/AN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AGNPXGENPREX1.0269 of 5 stars0.04.00.04.70.00.00.6ITRMIterum Therapeutics1.8659 of 5 stars3.53.00.00.02.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALIMAlimera Sciences 0.00N/AN/AN/ACLSNImunon 0.00N/AN/AN/AEVOKEvoke Pharma 0.00N/AN/AN/AGNPXGENPREX 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.00874.34% UpsideCurrent Analyst Ratings BreakdownLatest ALIM, EVOK, GNPX, CLSN, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALIMAlimera Sciences$99.68M2.91N/AN/A$0.88 per share6.30CLSNImunon$500K0.00N/AN/A$9.66 per share0.00EVOKEvoke Pharma$10.25M0.39N/AN/A$4.74 per share0.56GNPXGENPREXN/AN/AN/AN/A$0.15 per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALIMAlimera Sciences-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/ACLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AEVOKEvoke Pharma-$5.35M-$2.87N/A∞N/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)GNPXGENPREX-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)Latest ALIM, EVOK, GNPX, CLSN, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million5/12/2025Q1 2025GNPXGENPREX-$0.82-$0.26+$0.56-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALIMAlimera SciencesN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AGNPXGENPREXN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALIMAlimera Sciences1.802.792.62CLSNImunon0.136.526.52EVOKEvoke PharmaN/A1.551.50GNPXGENPREXN/A1.941.94ITRMIterum TherapeuticsN/A3.723.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALIMAlimera Sciences99.83%CLSNImunon12.97%EVOKEvoke PharmaN/AGNPXGENPREX14.05%ITRMIterum Therapeutics9.21%Insider OwnershipCompanyInsider OwnershipALIMAlimera Sciences31.40%CLSNImunon4.66%EVOKEvoke Pharma6.10%GNPXGENPREX8.47%ITRMIterum Therapeutics9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALIMAlimera Sciences15052.39 million35.94 millionOptionableCLSNImunon277.10 million6.77 millionOptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableGNPXGENPREX2027.82 million25.47 millionNo DataITRMIterum Therapeutics1040.00 million36.32 millionNot OptionableALIM, EVOK, GNPX, CLSN, and ITRM HeadlinesRecent News About These CompaniesIterum Therapeutics plc (ITRM) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comIterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMIterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comIterum Therapeutics appoints Coyne as CCOJune 30, 2025 | msn.comIterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial GrowthJune 30, 2025 | globenewswire.comITRM - Iterum Therapeutics PLC Chart - MorningstarJune 25, 2025 | morningstar.comMIterum Therapeutics Announces Publication of REASSURE Trial in NEJM EvidenceJune 25, 2025 | globenewswire.comIterum Therapeutics PLC: Iterum Therapeutics Announces Partnership for Commercialization ServicesJune 11, 2025 | finanznachrichten.deIterum Therapeutics Announces Partnership for Commercialization ServicesJune 11, 2025 | globenewswire.comIterum Therapeutics Announces Extension of Term of Promissory NoteMay 19, 2025 | globenewswire.comIterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...May 14, 2025 | finance.yahoo.comIterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026May 13, 2025 | msn.comIterum Therapeutics plc (ITRM) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comIterum Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comA Look Ahead: Iterum Therapeutics's Earnings ForecastMay 12, 2025 | benzinga.comIterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025May 6, 2025 | globenewswire.comIterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary SharesApril 30, 2025 | globenewswire.comIterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of SharesApril 29, 2025 | quiverquant.comQIterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary SharesApril 29, 2025 | globenewswire.comIterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of AntibioticsApril 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALIM, EVOK, GNPX, CLSN, and ITRM Company DescriptionsAlimera Sciences NASDAQ:ALIMAlimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Imunon NASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Evoke Pharma NASDAQ:EVOK$2.65 -0.07 (-2.57%) Closing price 07/7/2025 03:58 PM EasternExtended Trading$2.60 -0.05 (-2.08%) As of 07/7/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.GENPREX NASDAQ:GNPX$0.26 0.00 (-1.23%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.25 0.00 (-1.59%) As of 07/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Iterum Therapeutics NASDAQ:ITRM$0.92 -0.04 (-4.17%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.94 +0.02 (+2.31%) As of 07/7/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
